Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy.
Sharp AS, Tapp RJ, Thom SA, Francis DP, Hughes AD, Stanton AV, Zambanini A, O'Brien E, Chaturvedi N, Lyons S, Byrd S, Poulter NR, Sever PS, Mayet J; ASCOT Investigators. Sharp AS, et al. Among authors: zambanini a. Eur Heart J. 2010 Mar;31(6):747-52. doi: 10.1093/eurheartj/ehp498. Epub 2009 Nov 26. Eur Heart J. 2010. PMID: 19942604 Clinical Trial.
Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy.
Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, McG Thom SA, Hughes AD; Anglo-Scandinavian Cardiac Outcome Trial Investigators. Manisty CH, et al. Among authors: zambanini a. Hypertension. 2009 Oct;54(4):724-30. doi: 10.1161/HYPERTENSIONAHA.108.125740. Epub 2009 Aug 24. Hypertension. 2009. PMID: 19704107 Clinical Trial.
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators. Serruys PW, et al. Among authors: zambanini a. Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899. Epub 2008 Sep 1. Circulation. 2008. PMID: 18765397 Clinical Trial.
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G. Cobitz A, et al. Among authors: zambanini a. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81. doi: 10.1002/pds.1615. Pharmacoepidemiol Drug Saf. 2008. PMID: 18613278
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; RECORD Study Group. Komajda M, et al. Among authors: zambanini a. Cardiovasc Diabetol. 2008 Apr 24;7:10. doi: 10.1186/1475-2840-7-10. Cardiovasc Diabetol. 2008. PMID: 18435852 Free PMC article. Clinical Trial.
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP. Dargie HJ, et al. Among authors: zambanini a. J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. doi: 10.1016/j.jacc.2006.10.077. Epub 2007 Apr 6. J Am Coll Cardiol. 2007. PMID: 17448371 Free article. Clinical Trial.
24 results